Navigation Links
Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
Date:11/9/2010

ially successful or will effectively enhance our businesses or their market value, or that the MedPodium product line can be successfully broadened to include additional healthy lifestyle opportunities, or that we can effectively promote commercialization of our products on our own or through third parties; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the commercialization of Generx in the U.S. or other markets; that Nitric Oxide or other technologies we investigate can be used to effectively expand or improve our product portfolio; that our product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that our clinical study programs can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that the FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our depen
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
2. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
3. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
4. Cardium Regains Listing Compliance With NYSE Amex
5. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
6. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
7. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
8. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
9. Cardium Completes $6.0 Million Registered Direct Offering
10. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Diego, California (PRWEB) April 24, 2015 ... announced key milestones in its allogeneic stem-cell product ... Biopharma to properly reflect the corporate strategic direction. ... our allogeneic (donor) adipose stem cell development program ... completion of our cGMP manufacturing facility and hiring ...
(Date:4/24/2015)... SAN DIEGO , April 24, 2015  Pfenex ... in the development of biosimilar therapeutics including high value ... of its follow-on public offering of 6,000,000 shares of ... of $15.50 per share. Of the shares being offered, ... 3,390,000 shares are being offered by existing stockholders. Pfenex ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... Athena San Diego, an organization that accelerates ... San Diego’s technology and life science sectors, will announce ... their Gala on April 30, 2015 from 5-9pm at ... http://athenasd.org/events/ , The Pinnacle Awards recognize individuals and ... of fostering networking, risk taking and diversity of thought, ...
Breaking Biology Technology:Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... and BioMed Central are announcing the launch ... today, a new online community for ... opportunities and industry news. (Logo: ... http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) (Logo: http://photos.prnewswire.com/prnh/20100916/FL66006LOGO ...
... The PhD thesis by Carlos Echeverra Arrondo, Doctor in ... "On doped semiconductor quantum dots and magnetic nanowires", studied ... The interest aroused by nanoscience and nanotechnology spurred Dr ... their size is reduced to less than one hundred ...
... SIAL ) will be presenting at the UBS ... 12:30 PM ET in New York, NY. Interested parties may ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... Sigma-Aldrich is a leading Life Science and High Technology ...
Cached Biology Technology:BioSpace and BioMed Central Create Global Career Community 2Ph.D. study of behavior of semiconductor crystals of size less than 100 nanometers 2
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... This press release is available in French . ... Cancer (IRIC) of the Universit de Montral have identified a ... the origin of several cancers. In an article published in ... recent discovery of a protein complex that controls the RAS/MAPK ...
... have discovered a disease mechanism that links hereditary amyotrophic lateral ... and points to a possible therapeutic target. The findings ... Nature Neuroscience . ALS is an adult-onset disease ... three to five years of diagnosis. Scott Brady, ...
... accumulating in municipal landfills, and reliance on imported oil ... new ultra-light biodegradable foam plastic material made from two ... The new substance could be used in furniture cushions, ... ACS, Biomacromolecules , a monthly journal. ...
Cached Biology News:Discovery of a mechanism that controls the expression of a protein involved in numerous cancers 2Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3
...
... Nonanoyl-N-methylglucamide White solid. Water-soluble ... readily removed by dialysis. Useful reagent ... by HPLC. Absorbance (10%, H ... O. CMC 19 - 25 mM. ...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... Tecans MiniPrep series of robotic workstations ... The MiniPrep is the ideal automation ... automation of routine laboratory procedures, improving throughput, ... based Gemini for MiniPrep software allows you ...
Biology Products: